000			03737nam a22004335i 4500
001			978-1-4614-4732-0
003			DE-He213
005			20140220082816.0
007			cr nn 008mamaa
008			121116s2013 xxu| s |||| 0|eng d
020			_a9781461447320 _9978-1-4614-4732-0
024	7		_a10.1007/978-1-4614-4732-0 _2doi
050		4	_aRC261-271
072		7	_aMJCL _2bicssc
072		7	_aMED062000 _2bisacsh
082	0	4	_a614.5999 _223
100	1		_aCuriel, Tyler J. _eeditor.
245	1	0	_aCancer Immunotherapy _h[electronic resource] : _bParadigms, Practice and Promise / _cedited by Tyler J. Curiel.
264		1	_aNew York, NY : _bSpringer New York : _bImprint: Springer, _c2013.
300			_aIX, 483 p. 19 illus., 16 illus. in color. _bonline resource.
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
347			_atext file _bPDF _2rda
505	0		_aIntroduction -- Historical Perspectives and Current Trends in Cancer Immunotherapy -- T cell and Antigen-Presenting Cell Subsets in the Tumor Microenvironment -- Adoptive T Cell Transfer -- Dendritic Cell-Based Cancer Immunotherapy: Achievements and novel concepts -- Peptide and Protein-based Cancer Vaccines -- Antigen Targeting to Dendritic Cells for Cancer Immunotherapy -- Cytokines in the Treatment of Cancer -- Immune Co-signaling to Treat Cance -- Managing Regulatory T cells -- Myeloid-Derived Suppressor Cells in Cancer: Mechanisms and therapeutic perspectives -- Antibodies as Cancer Immunotherapy -- Targeted Toxins in Cancer Immunotherapy -- Miscellaneous Approaches and Considerations: TLR agonists and other inflammatory agents, anti-chemokine agents, infectious agents, tumor stroma targeting, age and sex effects, and miscellaneous small molecules -- Issues in Pre-clinical Models, Clinical Trial Design and Analytical Considerations in Developing and Evaluating Novel Cancer Immunotherapies -- Monitoring Antigen-Specific Responses in Clinical Trials of Immunotherapy -- Index.
520			_aThis volume is a comprehensive discussion of the major factors affecting tumor immunology and a discussion of all major anti-cancer immunotherapeutic agents approved by the Food and Drug Administration of the United States and by European agencies. Many promising but unapproved agents in clinical trials are also discussed, as are key pre-clinical developments. The major challenges and intellectual issues facing investigators developing novel immunotherapeutics are discussed in detail as are conceptual developments influencing current and future treatment strategies. Each chapter begins by defining all relevant key terms and concepts and provides pertinent background information so that the text will be accessible to newcomers to the field as well as to the expert. This text book should provide an excellent reference resource for investigators in tumor immunology, life sciences students, drug developers designing novel anti-cancer immunotherapeutics, and to other individuals with some scientific training wishing to gain a better understanding of the field of tumor immunotherapy. Although the field is evolving rapidly, we have taken pains to ensure that information was as up to date as possible as the text went to press.
650		0	_aMedicine.
650		0	_aOncology.
650		0	_aToxicology.
650	1	4	_aBiomedicine.
650	2	4	_aCancer Research.
650	2	4	_aPharmacology/Toxicology.
710	2		_aSpringerLink (Online service)
773	0		_tSpringer eBooks
776	0	8	_iPrinted edition: _z9781461447313
856	4	0	_uhttp://dx.doi.org/10.1007/978-1-4614-4732-0
912			_aZDB-2-SBL
999			_c95212 _d95212